Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Stevens-Johnson syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Stevens-Johnson syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Macular amyloidosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Macular amyloidosis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Erythema multiforme Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Erythema multiforme indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Primary localized cutaneous nodular amyloidosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Primary localized cutaneous nodular amyloidosis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
8 min read
KSP-0914 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
KSP-0914: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IMSB-301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
IMSB-301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NVP-1603 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
NVP-1603: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TQB3019 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
TQB3019: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AMT-562 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
AMT-562: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SKB445 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
SKB445: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BAY-3498264 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
BAY-3498264: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RSV mRNA vaccine(CSPC Megalith Biopharmaceutial) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
RSV mRNA vaccine(CSPC Megalith Biopharmaceutial): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.